Does the co-delivery of oxaliplatin abrogate the immunogenic response to PEGylated siRNA-lipoplex?
Our results suggest that, besides the expected therapeutic efficacy of co-administration, encapsulation of l-OHP into the PEGylated siRNA-lipoplex has great potential for minimizing the immunostimulation of PEGylated siRNA-lipoplex, resulting in a safe, applicable, and compliant treatment regimen for sequential clinical administration.
Slk19 is required to avoid aberrant segregation of chromosomes in meiosis I and II and in mitosis. We suggest that the absence of Slk19 leads to uncoupling of chromosome movement from completion of microtubule attachment and resolution of chromosome cohesion.